Imcivree

Setmelanotide, the active ingredient in Imcivree, is a melanocortin 4 receptor (MC4R) agonist presented as a 1 mg/mL subcutaneous injection solution for subcutaneous use. It is indicated for the treatment of obesity associated with specific genetic deficiencies, including proopiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, leptin receptor (LEPR) deficiency, Bardet‑Biedl syndrome, and Alström syndrome.

GNH USA supplies Imcivree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Imcivree targets rare genetic forms of obesity by modulating the melanocortin pathway. It is prescribed for the following conditions: - Obesity due to POMC deficiency: reduces appetite and promotes weight loss in patients with this genetic form of obesity. - Obesity due to PCSK1 deficiency: helps control body weight by enhancing energy expenditure. - Obesity due to LEPR deficiency: improves satiety signaling and supports weight reduction. - Obesity associated with Bardet‑Biedl syndrome: assists in managing excess weight linked to this ciliopathy. - Obesity associated with Alström syndrome: contributes to weight management in this multisystem disorder.

Imcivree may cause a range of adverse reactions. Monitoring and reporting are essential for patient safety.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Nausea: feeling of queasiness that may occur after dosing. - Headache: mild to moderate head discomfort. - Hyperpigmentation: darkening of the skin, particularly around the injection area.

Serious or Rare Side Effects: - Severe injection site infection: signs of cellulitis or abscess requiring medical attention. - Hypersensitivity reactions: rash, itching, or anaphylaxis in rare cases. - Marked hyperpigmentation: extensive skin darkening that may be disfiguring.

Before initiating Imcivree, clinicians should consider several safety aspects. - Pregnancy: safety not established; avoid unless potential benefit justifies the risk. - Breastfeeding: unknown effects; weigh maternal benefit against potential infant exposure. - Renal impairment: monitor renal function as clearance may be affected. - Cardiovascular disease: observe blood pressure and heart rate during therapy. - Concomitant melanocortin agonists: avoid due to additive pharmacologic activity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imcivree can interact with other medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Other MC4R agonists: additive effect may increase risk of adverse events. - Immunosuppressive agents: may impair wound healing at injection sites.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: monitor blood pressure for potential changes. - Antidiabetic medications: observe glucose levels as weight loss can affect glycemic control. - Live vaccines: consider timing as immune modulation could alter vaccine response.